

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) February 22, 2024

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

(Commission File Number)

22-0760120

(IRS Employer Identification No.)

1 Becton Drive,

Franklin Lakes,

New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class</u>	<u>Trading Symbol</u>	<u>Name of each exchange on which registered</u>
Common stock, par value \$1.00	BDX	New York Stock Exchange
1.900% Notes due December 15, 2026	BDX26	New York Stock Exchange
3.020% Notes due May 24, 2025	BDX25	New York Stock Exchange
1.208% Notes due June 4, 2026	BDX/26A	New York Stock Exchange
1.213% Notes due February 12, 2036	BDX/36	New York Stock Exchange
0.034% Notes due August 13, 2025	BDX25A	New York Stock Exchange
3.519% Notes due February 8, 2031	BDX31	New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).		
		Emerging growth company <input type="checkbox"/>
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <input type="checkbox"/>		
<hr/>		

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 22, 2024, David Hickey, Executive Vice President and President of the Life Sciences segment of Becton, Dickinson and Company ("BD"), informed BD of his intention to retire, effective July 1, 2024. BD intends to name a successor to Mr. Hickey prior to his retirement date.

ITEM 7.01. Regulation FD Disclosure.

On February 27, 2024, BD issued a press release relating to the matters described above in Item 5.02. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Item 7.01 shall neither be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit [99.1](#) Press release dated February 27, 2024, which is furnished pursuant to Item 7.01.

Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: _____ /s/ Gary DeFazio
Gary DeFazio
Senior Vice President and Corporate Secretary

Date: February 27, 2024



NEWS RELEASE

Dave Hickey Announces Intent to Retire from BD

FRANKLIN LAKES, N.J. (Feb. 27, 2024) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Dave Hickey has informed the company of his intent to retire from BD, effective July 1.

Hickey is currently executive vice president and president of the Life Sciences segment for BD, a position he has held since January 2021. Prior to his current role, Hickey was president of Integrated Diagnostic Solutions from 2019 to 2021, and president of Diagnostic Systems prior to that. Before joining BD in 2014, Hickey served in a range of executive leadership positions at Siemens Healthcare.

"For over a decade at BD, Dave has demonstrated a strong, strategic and innovative approach, empowering his teams to deliver impactful results through a growth mindset and developing incredible talent and next-gen leaders at BD," said Tom Polen, chairman, CEO and president of BD. "I want to express BD's sincere gratitude to Dave for his significant contributions to BD, especially during the COVID-19 pandemic, where he led the BD effort to develop numerous rapid and molecular diagnostic tests in record time to support health care providers and patients around the world. We wish him all the best in his well-deserved retirement."

BD intends to name a successor to Hickey prior to his retirement date.

"Throughout my career, I've been most driven by the people I have had the privilege to lead, and the important work we've done to help patients around the world," Hickey said. "In my 10 years at BD, I've worked alongside some of the most incredible and talented teams in MedTech who have delivered countless research and diagnostic innovations, and who are having a profound impact on people around the world. I'm incredibly proud of what we've accomplished together and am confident in the continued success of BD now and in the future."

###

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) [@BDandCo](https://twitter.com/BDandCo) or Instagram [@becton_dickinson](https://www.instagram.com/becton_dickinson).

Contacts:

Media: Investors:

Troy Kirkpatrick Adam Reiffe

VP, Public Relations Sr. Director, Investor Relations

858.617.2361 201.847.6927

troy.kirkpatrick@bd.com adam.reiffe@bd.com